AVP and type 2 diabetes mellitus: Sundry studies have found that increased AVP release (commonly assessed by quantification of the surrogate precursor product copeptin) is associated with insulin resistance, type 2 diabetes and major cardiovascular events that characterise the metabolic syndrome24–27.